Business Details
Transforming Autoimmune Disease Treatment
At Aurinia, we are dedicated to transforming the treatment landscape for autoimmune diseases through relentless innovation and scientific excellence. Since introducing LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis, our team has focused on addressing high unmet medical needs with groundbreaking therapies. Our pipeline, including aritinercept (AUR200), reflects our commitment to advancing dual inhibitors of BAFF and APRIL for autoimmune conditions.Guided by our valuesAchieve Together, Collaborate, Explore & Build, and Act Responsiblywe prioritize patient-centered care and operational integrity. The lotus motif in our branding symbolizes resilience and our pursuit of therapies that become the gold standard. With a global presence spanning Edmonton and Rockville, we combine scientific rigor with ethical accountability to change the trajectory of autoimmune diseases.
Services
Autoimmune Disease Therapies
Lupus Nephritis Treatment
Medical Research
Drug Development
Clinical Trials
Highlights and features
- Our pipeline combines autoimmune disease expertise with dual-inhibitor technology.
- We pioneered the first FDA-approved oral therapy for lupus nephritis.
- Values-driven operations ensure ethical accountability and patient-centricity.
- Global team leverages decades of collective experience in pharmaceutical innovation.
- Lotus-inspired resilience drives continuous pursuit of gold-standard therapies.
Services
Lupus Nephritis Treatment
LUPKYNIS (voclosporin) is an FDA-approved oral therapy designed to treat active lupus nephritis, a severe kidney complication of systemic lupus erythematosus. By suppressing overactive immune responses, it aims to preserve renal function and improve long-term patient outcomes. This breakthrough treatment represents a significant advancement in autoimmune disease management, offering a targeted approach with clinical evidence supporting reduced proteinuria and increased remission rates.
Autoimmune Disease Research
Our research focuses on developing novel therapies for autoimmune disorders through cutting-edge immunology platforms. By targeting key pathways like BAFF and APRIL, we aim to modulate immune responses while maintaining protective immunity. Current efforts prioritize aritinercept (AUR200), a dual inhibitor in clinical trials, which could address conditions including lupus and IgA nephropathy. This work builds on decades of autoimmune disease expertise to deliver transformational treatments.
Clinical Trials
We conduct rigorous clinical trials to evaluate new therapies' safety and efficacy for autoimmune conditions. These studies follow strict regulatory guidelines and prioritize patient safety through comprehensive monitoring. Participants gain access to investigational treatments while contributing to medical advancements. Trials are conducted across global sites, ensuring diverse patient representation and accelerating data collection for regulatory submissions.
Questions
What autoimmune diseases does Aurinia target?
We focus on high-unmet-need conditions like lupus nephritis, with pipeline candidates addressing IgA nephropathy and other autoimmune disorders through BAFF/APRIL inhibition.
Is LUPKYNIS FDA-approved?
Yes, LUPKYNIS received FDA approval in January 2021 as the first oral therapy for adult patients with active lupus nephritis.
What is aritinercept (AUR200)?
Aritinercept is a dual BAFF/APRIL inhibitor in clinical development to treat autoimmune diseases by targeting key pathways involved in B-cell activation and survival.
How does Aurinia's pipeline differ from existing treatments?
Our therapies use novel mechanisms like dual inhibition of BAFF and APRIL to offer improved efficacy and safety profiles compared to traditional immunosuppressants.
Where are Aurinia's offices located?
Our corporate headquarters are in Edmonton, Alberta, with a US office in Rockville, Maryland.
